Physician profile
David Lott
NPI 1558859884
$14,622.53
in general payments reported to CMS, 2019-2025
32 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.01 · 2020: $11.48 · 2021: $478 · 2022: $958 · 2023: $536 · 2024: $1,132 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $2,953 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
| Food and Beverage | $2,953.29 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11,050.55 | 2021-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $506.55 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $407.58 | 2021-2025 | |
| Novo Nordisk INC | $395.46 | 2020-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $379.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $369.08 | 2021-2025 | Korlym |
| Tandem Diabetes Care, INC. | $205.64 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.23 | 2021-2025 | Jardiance |
| Inspire Medical Systems, INC. | $132.44 | 2024 | Inspire |
| Averitas Pharma INC. | $115.89 | 2023-2025 | Qutenza |
| Insulet Corporation | $96.59 | 2022-2024 | Omnipod |
| Dexcom, INC. | $93.81 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $71.54 | 2019-2022 | |
| Medtronic, INC. | $71.47 | 2023-2025 | Minimed 780g |
| Antares Pharma, INC. | $52.02 | 2024 | Xyosted |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.16 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $48.46 | 2023 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $45.09 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $43.60 | 2025 | Farxiga |
| Enterra Medical, INC. | $36.81 | 2024 | |
| Ascendis Pharma Endocrinology INC | $33.48 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $32.56 | 2021 | |
| Kyowa Kirin, INC. | $25.52 | 2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $24.23 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.94 | 2024 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 | |
| Beta Bionics, INC. | $18.96 | 2024 | Ilet Bionic Pancreas |
| Nevro Corp. | $17.72 | 2022 | |
| Madrigal Pharmaceuticals | $17.54 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $15.95 | 2021 | |
| Ibsa Pharma INC. | $14.78 | 2023 | Tirosint, Licart |
| Cequr Corporation | $14.62 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.